Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)

NCT01086761 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT01086761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01086761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)
Lead sponsor
Allergan
Phase
Phase 1
Overall status
Terminated
Start date
March 31, 2010
Completion date
November 30, 2010
Enrollment
32 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration